New quadruple therapy shows promise in battling multiple myeloma

NCT ID NCT03710603

First seen Feb 17, 2026 · Last updated May 14, 2026 · Updated 14 times

Summary

This study tests whether adding the drug daratumumab to a standard three-drug combination (VRd) helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 709 patients aged 18 to 70 who are healthy enough for high-dose therapy will take part. The main goal is to see if the four-drug combo delays disease progression better than the three-drug combo alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Australia

  • Ankara University

    Ankara, Turkey (Türkiye)

  • Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona

    Ancona, Italy

  • CHRU Hôtel Dieu

    Nantes, France

  • Erasmus MC

    Rotterdam, Netherlands

  • Hospital Clinic I Provincial de Barcelona

    Barcelona, Spain

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • Odense University Hospital

    Odense, Denmark

  • Oslo University Hospital

    Oslo, Norway

  • Regional General Hospital Alexandra

    Athens, Greece

  • University Hospital Leuven

    Leuven, Belgium

  • University Hospital Ostrava

    Ostrava, Czechia

  • Uniwersytet Jagiellonski Collegium Medicum

    Krakow, Poland

Conditions

Explore the condition pages connected to this study.